Document Detail

A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.
MedLine Citation:
PMID:  22451016     Owner:  NLM     Status:  MEDLINE    
We conducted a pharmacokinetic (PK) study of mitoxantrone (Novantrone®), a clinically well-established anticancer agent, in mice and developed a mechanism-based PBPK (physiologically based pharmacokinetic) model to describe its disposition. Mitoxantrone concentrations in plasma and six organs (lung, heart, liver, kidney, spleen, and brain) were determined after a 5 mg/kg i.v. dose. We evaluated three different PBPK models in order to characterize our experimental data: model 1 containing Kp values, model 2 incorporating a deep binding compartment, and model 3 incorporating binding of mitoxantrone to DNA and protein. Among the three models, only model 3 with DNA and protein binding captured all the experimental data well. The estimated binding affinity for DNA (K (DNA)) and protein (K (macro)) were 0.0013 and 1.44 μM, respectively. Predicted plasma and tissue AUC values differed from observed values by <19 %, except for heart (60 %). Model 3 was further used to simulate plasma mitoxantrone concentrations in humans for a 12-mg/m(2) dose, using human physiological parameters. The simulated results generally agreed with the observed time course of mitoxantrone plasma concentrations in patients after a standard dose of 12 mg/m(2). In summary, we reported for the first time a mechanism-based PBPK model of mitoxantrone incorporating macromolecule binding which may have clinical applicability in optimizing clinical therapy. Since mitoxantrone is a substrate of the efflux transporters ABCG2 and ABCB1, the incorporation of efflux transporters may also be necessary to characterize the data obtained in low-dose studies.
Guohua An; Marilyn E Morris
Related Documents :
11768626 - Neurochemical findings in the mptp model of parkinson's disease.
25226926 - Digital design and fabrication of simulation model for measuring orthodontic force.
22111646 - Ikiugu's eclectic method of combining theoretical conceptual practice models in occupat...
22451016 - A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to h...
16023866 - Spatiotemporal bayesian inference dipole analysis for meg neuroimaging data.
20410716 - Genetic variance for autism screening items in an unselected sample of toddler-age twins.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-03-27
Journal Detail:
Title:  The AAPS journal     Volume:  14     ISSN:  1550-7416     ISO Abbreviation:  AAPS J     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-04-24     Completed Date:  2013-01-28     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101223209     Medline TA:  AAPS J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  352-64     Citation Subset:  IM    
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 517 Hochstetter Hall, Amherst, New York 14260-1200, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA / blood,  metabolism*
Mitoxantrone / blood,  pharmacokinetics*
Models, Biological*
Protein Binding / physiology
Tissue Distribution / drug effects,  physiology
Reg. No./Substance:
65271-80-9/Mitoxantrone; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of language concordant, patient-centered drug label instructions.
Next Document:  Perinatal Depression Screening in Healthy Start: An Evaluation of the Acceptability of Technical Ass...